The pharmaceutical community is buzzing about retatrutide, a novel dual GIP and GLP-1 agonist that’s showing remarkable promise in {weight management trials. Early findings from the SURPASS-2 study indicate that this https://sociallweb.com/story7133839/retatrutide-the-new-weight-loss-hope